Skip banner and top navigation
NHLBI Logo and Link
National Heart, Lung, and Blood Institute: People, Science, Health
 HOME  SITE INDEX  CONTACT US
  
  Patient Recruitment - Leukemia
TIPS     ADVANCED SEARCH
 

Research Studies        
Autologous NK cell infusions in treatment resistant CLL and CML   Ofatumumab for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma   PCI-32765 for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) in patients 65 & older or have a 17p deletion  
Escalating Doses of ON 01910.Na for Leukemia   Partially Matched DLI to Treat Relapsed Leukemia   Stem Cell Transplant and T Cell Add Back to Treat Leukemia
Natural History of MBL, CLL and SLL  

Leukemia Research Study

Autologous NK cell infusions in treatment resistant CLL and CML

If you (or someone you know) has CLL or CML that is not responding to standard treatments, you may be able to participate in our phase 1 clinical trial designed to evaluate the safety of a new type of cell transplant. Specifically, we are testing the safety and tolerability of the infusion of one type of your own white blood cells called NK cells.

In this research project your NK cells will be collected, reproduced in large numbers in the laboratory and then given back to you as an infusion. Before the cells are given back, you will receive two chemotherapy agents: pentostatin, to suppress your immune system and prevent it from attacking the infused NK cells, and bortezomib, to increase the anti-tumor activity of the NK cells. You will also receive the drug interleukin-2 to maintain NK cell activity. You are required to return to the Clinical Center for frequent safety monitoring over a 7 week period of protocol participation. If you respond you may have the option to continue NK cell infusions.

To find out if you qualify, please call us toll free at 1-800-411-1222 (TTY 1-866-411-1010). Our email address is BloodStudy@nhlbi.nih.gov

 
Email This Study To A Friend       View/Print PDF Version Of This Study

Protocol Information

Disease and Treatment Information

Support Groups
 

 

Leukemia Research Study

Escalating Doses of ON 01910.Na for Leukemia

Hematologists at the National Heart, Lung, and Blood Institute are investigating a new treatment for chronic lymphocytic leukemia (CLL) and Hairy cell Leukemia. The study drug, ON01910.Na is classified as mitotic inhibitor and works by interrupting the life cycle of leukemia cells. Consenting subjects will receive 2 days of drug infusion once every other week (1 cycle) for a minimum of 2 cycles. Subjects without toxicity will have the option to continue the regimen for 2 additional cycles, after which if there is evidence of response, subjects may continue the regimen indefinitely.

If you are between the ages of 18 and 99 and have been diagnosed with CLL and have failed to respond to, relapsed following, are not eligible for, or opted not to participate in other standard of care treatment options you may be able to participate in a clinical trial. This study will determine what dose and which dosing schedule of this new drug is safe. We will also evaluate whether or not this drug can slow progression of your illness, improve blood counts, and/or reduce the need for transfusions of blood and/or platelets.

To find out if you qualify, please call our study coordinator at 301-402-0797 or email us at BloodStudy@nhlbi.nih.gov
 
Email This Study To A Friend       View/Print PDF Version Of This Study

Protocol Information

Disease and Treatment Information

Support Groups
 

 

Leukemia Research Study

Natural History of MBL, CLL and SLL

The Hematology Branch of the National Heart, Lung, and Blood Institute is conducting a clinical study for previously untreated patients with Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Leukemia (SLL) or Monoclonal B cell lymphocytosis (MBL). Although all three diseases are considered a type of blood cancer involving B-lymphocytes, CLL involves the peripheral blood, SLL mostly involves the lymph nodes, and MBL is thought to be the earliest diagnostic stage of CLL/SLL.

Most patients with CLL/SLL/MBL do not require treatment at the time of diagnosis and are observed following a "watch and wait" approach. This study provides state of the art diagnostic workup, regular follow-up monitoring, and sample collection during the "watch and wait" period. If treatment becomes necessary, patients will receive information on possible standard treatment options and research studies available at NIH.

If you choose to participate, you will undergo tests and procedures designed to evaluate the status of your disease. You will also have the opportunity to donate blood and tissue samples that will be used in laboratory research experiments designed to help us better understand MBL/CLL/SLL.

If you or someone you know has been diagnosed with MBL, CLL, or SLL you (they) may be able to participate in this study. To find out if you qualify, please contact our research coordinator at (301) 402-0797 or email us at BloodStudy@nhlbi.nih.gov

 
Email This Study To A Friend       View/Print PDF Version Of This Study

Protocol Information

Disease and Treatment Information

Support Groups
 

 

Leukemia Research Study

Ofatumumab for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma

The purpose of this study is to evaluate the efficacy of ofatumumab in combination with chemotherapy for previously untreated patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma(SLL). Ofatumumab is FDA approved for treating CLL/SLL that is not responsive to other drugs.

Participants will receive treatment at the NIH Clinical Center Day hospital and will be regularly scheduled for clinic visits at the NIH to evaluate the response to treatment. There is no charge for study-related medications, laboratory tests or examinations. Financial support towards the cost of lodging and travel is available based on NIH guidelines.
For questions about this study, please contact the research coordinator, Tel. No. 301- 402-0797 or BloodStudy@nhlbi.nih.gov

 
Email This Study To A Friend       View/Print PDF Version Of This Study

Protocol Information
 

 

Leukemia Research Study

Partially Matched DLI to Treat Relapsed Leukemia

If you or someone you know is diagnosed with ALL, AML, or CML and have relapsed within 6 months of receiving a stem cell transplant, you may be able to participate in our clinical trial designed to evaluate the effectiveness of a partially HLA matched infusion of donor lymphocytes (DLI). Specifically, we are testing whether giving an infusion of donor lymphocytes from a partially matched family member will maximize the antileukemia effect of following an HLA matched allogeneic stem cell transplant. To achieve at least temporary engraftment of the DLI and disease control, cyclophosphamide and fludarabine immunosuppression will be given prior to the DLI.

To find out if you qualify, please contact our research coordinator at (301) 496-3841 or by email at BloodStudy@nhlbi.nih.gov


 
Email This Study To A Friend       View/Print PDF Version Of This Study

Protocol Information

Disease and Treatment Information

Support Groups
 

 

Leukemia Research Study

PCI-32765 for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) in patients 65 & older or have a 17p deletion

This study will investigate the efficacy of PCI-32765 in patients with chronic lymphocytic leukemia (CLL) / small lymphocytic lymphoma (SLL) who are older than 65 or those patients with a 17p deletion. Recent studies indicated that PCI-32765 may inhibit cell proliferation. This protocol is intended both for patients who are untreated and those who have previously been treated. Oral PCI-32765 tablets will be distributed by the NIH and administered at the patient's home. Patients will be followed for a total of 12 months at the NIH. There is no charge for medications, laboratory tests, examinations, procedures and/or clinic visits performed as part of this study. If you have any questions about this study, contact the research nurse, Tel. No. (301)402-0797
 
Email This Study To A Friend       View/Print PDF Version Of This Study

Disease and Treatment Information
 

 

Leukemia Research Study

Stem Cell Transplant and T Cell Add Back to Treat Leukemia

If you or someone you know is diagnosed with acute lymphocytic leukemia (ALL), acute myelogenous leukemia (AML), chronic lymphocytic leukemia (CLL), or chronic myrlogenous leukemia (CML), you may be able to participate in our clinical trial designed to investigate methods of making stem cell transplant procedures safer and more effective. Specifically, we are testing whether special treatment of donor stem cells and delaying the transfusion of donor immune cells will reduce complications and improve transplant outcome. You must have an HLA-matched brother or sister who is willing to participate as a donor in order to participate in this study.

To find out if you qualify, please contact our research coordinator at (301) 496-3841 or by email at BloodStudy@nhlbi.nih.gov

 
Email This Study To A Friend       View/Print PDF Version Of This Study

Protocol Information

Disease and Treatment Information

Support Groups
 

 
 
Spacer

NHLBI HOME · ACCESSIBILITY INFORMATION · NHLBI AT THE CLINICAL CENTER · PRIVACY STATEMENT · WEB TECHNICAL CONTACT